



**To:** MaineCare Providers  
**From:** Anne-Marie Toderico, Director of Pharmacy  
**Date:** 02/03/2023  
**Re:** PDL Update for 02/03/223

## MaineCare PDL Update for February 3, 2023

The following medication(s) have been recently added/changed to the MaineCare PDL as **non-preferred** and will require prior authorization:

- Buphenyl Powder
- Carbaglu Tabs
- Cimerli
- Fylnetra
- Korsuva
- Pheburane Granules
- Ravicti Liquid
- Ryaltris
- Sodium Phenylbutyrate Powder
- Sodium Phenylbutyrate Tab
- Sotyktu
- Spevigo
- Verkazia
- Vivjoa
- Zonisade
- Zoryve
- Ztalmy

The following medication(s) have recently been added to the MaineCare PDL as **preferred** and will **not** require a prior authorization:

- Buphenyl Tablet
- Carglumic Acid Tabs
- Cyclosporine Opth 0.05%
- Gamunex-C
- Lucentis

The following medication(s) have recently been added to the MaineCare PDL as **non-preferred** with new PDL criteria:

- Auvelity: Use of individual ingredients or other medications preferred.
- Enjaymo: Indicated to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
- Entadfi: Use of individual ingredients preferred (Finasteride and tadalafil). It is not recommended for more than 26 weeks.
- Tadliq: Approvals will require WHO Group 1 with NYHA Functional Class II-III.
- Hyftor: Clinical PA required for appropriate diagnosis and clinical parameters. For the treatment of patients  $\geq 6$  years of age.
- Xenpozyme: Clinical PA required for appropriate diagnosis and clinical parameters. For treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

The following medication (s) have recently been removed from the MaineCare PDL.

- Aczone
- Flebogamma Dif
- Slow FE TBCR